Angeion files for Sentinel investigational device exemption (IDE):
This article was originally published in Clinica
Executive Summary
Angeion (US) has filed for an investigational device exemption with the FDA to allow it to conduct human clinical trials for its Sentinel implantable cardioverter defibrillator in the US. The company has also filed for a CE marking in Europe.